We are live on ! Find out more
AVM

Arch Venture Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 356.62%
This Fund
S&P 500
This Quarter Est. Return
+14.26%
1 Year Est. Return
+356.62%
3 Year Est. Return
+228.31%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.1B
AUM Growth
+$423M
Cap. Flow
+$288M
Cap. Flow %
26.16%
Top 10 Hldgs %
99.27%
Holding
13
New
3
Increased
–
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
PBLS
Parabilis Medicines Inc
PBLS
+$177M
2
SPTX
Seaport Therapeutics
SPTX
+$111M
3
BOLD
Boundless Bio
BOLD
+$4.15M

Top Sells

Rank Stock Value
1
VIR icon
Vir Biotechnology
VIR
+$2.12M
2
QTTB icon
Q32 Bio
QTTB
+$2.06M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PBLS
1
Parabilis Medicines Inc
PBLS
$4.56B
$176M 15.95%
+6,412,780
New +$177M
BEAM icon
2
Beam Therapeutics
BEAM
$2.48B
$156M 14.16%
4,540,132
– –
RAPP
3
Rapport Therapeutics
RAPP
$2.09B
$155M 14.12%
3,728,738
– –
SPTX
4
Seaport Therapeutics
SPTX
$1.25B
$137M 12.42%
+6,294,951
New +$111M
ERAS icon
5
Erasca
ERAS
$5.55B
$130M 11.81%
7,091,557
– –
VIR icon
6
Vir Biotechnology
VIR
$1.8B
$129M 11.76%
12,694,163
-222,500
-2% -$2.12M
MAZE
7
Maze Therapeutics
MAZE
$1.37B
$123M 11.18%
4,120,053
– –
LYEL icon
8
Lyell Immunopharma
LYEL
$293M
$45.5M 4.14%
3,247,162
– –
GENB
9
Generate Biomedicines
GENB
$2.02B
$32.8M 2.98%
1,944,426
– –
TXG icon
10
10x Genomics
TXG
$8.94B
$8.35M 0.76%
217,834
– –
BOLD
11
Boundless Bio
BOLD
$64.4M
$6.74M 0.61%
+2,694,095
New +$4.15M
GOSS icon
12
Gossamer Bio
GOSS
$65.6M
$1.33M 0.12%
100,699
– –
QTTB icon
13
Q32 Bio
QTTB
$330M
– –
-320,482
Closed -$2.06M

Similar funds

BFG
Beacon Financial Group Dallas, Texas $1.1B AUM 21.5% 1-Year Est. Return
UWPG
Ullmann Wealth Partners Group Jacksonville Beach, Florida $1.1B AUM 21.23% 1-Year Est. Return
DI
DUMAC Inc Durham, North Carolina $1.1B AUM
BI
BBFIT Investments Singapore $1.1B AUM
TAMH
Taikang Asset Management (HK) Hong Kong $1.1B AUM 50.43% 1-Year Est. Return
SPC
Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return
RA
Rodgers & Associates Lancaster, Pennsylvania $1.1B AUM 20.77% 1-Year Est. Return
TSW
Three Seasons Wealth Salt Lake City, Utah $1.1B AUM 50.99% 1-Year Est. Return

Arch Venture Management's Q2 2026 Portfolio in Review

As of Q2 2026, Arch Venture Management held 13 positions worth $1.1B, up 62% from $677M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Arch Venture Management deployed $288M of net new capital in Q2 2026, opening 3 new positions. Its largest new stake was Parabilis Medicines Inc: 6,412,780 shares worth $176M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Vir Biotechnology, an estimated $2.12M trimmed.

  • Arch Venture Management's largest Q2 2026 buy was Parabilis Medicines Inc: 6,412,780 shares worth $176M.
  • Arch Venture Management's biggest Q2 2026 reduction was Vir Biotechnology, cutting an estimated $2.12M.
  • Arch Venture Management fully exited Q32 Bio in Q2 2026, selling an estimated $2.06M.
  • Arch Venture Management's ten largest holdings make up 99% of its $1.1B portfolio in Q2 2026.
  • Arch Venture Management opened 3 new positions and closed 1 in Q2 2026.
  • Arch Venture Management's portfolio value rose 62% quarter-over-quarter to $1.1B.

Based on Arch Venture Management's 13F filing for Q2 2026, filed 14 Aug 2026.